Company GENB AS Other OTC

Equities

US3723032062

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

DKK in Million	2022	Weight	2023	Weight	Delta
Antibody Therapeutics 100.0 %	14,595	100.0 %	16,474	100.0 %	+12.87%

DKK in Million	2022	Weight	2023	Weight	Delta
Denmark 97.4 %	14,595	100.0 %	16,053	97.4 %	+9.99%
United States 2.3 %	0	0.0 %	380	2.3 %	-
Japan 0.2 %	0	0.0 %	41	0.2 %	-

Managers	Title	Age	Since
Jan van de Winkel CEO	Chief Executive Officer	63	31/12/98
Anthony Pagano DFI	Director of Finance/CFO	46	31/12/06
Anthony Mancini COO	Chief Operating Officer	53	22/03/20
Tahamtan Ahmadi CTO	Chief Tech/Sci/R&D Officer	51	31/12/16
Marisol Peron IRO	Public Communications Contact	-	10/03/19
Christopher Cozic HRO	Human Resources Officer	46	-
Judith Klimovsky PRN	Corporate Officer/Principal	67	08/02/17
Martine van Vugt PRN	Corporate Officer/Principal	71	31/12/00
Birgitte Stephensen LAW	General Counsel	63	31/12/01

Members of the board	Title	Age	Since
Deirdre Connelly CHM	Chairman	63	31/12/16
Anders Gersel Pedersen BRD	Director/Board Member	73	31/10/03
Rolf K. Hoffmann BRD	Director/Board Member	64	31/12/15
Elizabeth O'Farrell BRD	Director/Board Member	59	28/03/22
Pernille Erenbjerg BRD	Director/Board Member	57	31/12/14
Paolo Augusto Paoletti BRD	Director/Board Member	73	31/12/14
Mijke Zachariasse BRD	Director/Board Member	51	28/03/19
Martin Schultz BRD	Director/Board Member	49	31/12/21
Takahiro Hamatani BRD	Director/Board Member	50	31/12/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	66,129,923	65,143,457 ( 98.51 %)	981,465 ( 1.484 %)	98.51 %

Name	Equities	%	Valuation
Wellington Management Co. LLP 4.896 %	3,237,113	4.896 %	908 M $
GENMAB A/S 2.846 %	1,881,559	2.846 %	528 M $
Jan van de Winkel 0.9082 %	600,497	0.9082 %	168 M $
Nykredit Bank A/S (Investment Management) 0.4632 %	306,295	0.4632 %	86 M $
Amundi Asset Management SA (Investment Management) 0.3156 %	208,668	0.3156 %	59 M $
Danske Bank A/S (Investment Management) 0.2283 %	150,968	0.2283 %	42 M $
Robert W. Baird & Co., Inc. (Equity) 0.1861 %	123,067	0.1861 %	35 M $
State Street Global Advisors Ltd. 0.1695 %	112,073	0.1695 %	31 M $
Sjunde AP-fonden 0.1444 %	95,465	0.1444 %	27 M $
S.W. Mitchell Capital LLP 0.1354 %	89,501	0.1354 %	25 M $

Name	Equities	%	Valuation
AllianceBernstein LP 2.307 %	15,254,347	2.307 %	419 M $
BlackRock Advisors LLC 0.7591 %	5,019,269	0.7591 %	138 M $
Capital Research & Management Co. (International Investors) 0.6614 %	4,373,277	0.6614 %	120 M $
Harding Loevner LP 0.4983 %	3,294,728	0.4983 %	90 M $
Wellington Management Co. LLP 0.3526 %	2,331,814	0.3526 %	64 M $
RBC CMA LLC 0.2732 %	1,806,502	0.2732 %	50 M $
Renaissance Technologies LLC 0.2055 %	1,358,600	0.2055 %	37 M $
Wells Fargo Bank NA 0.1931 %	1,276,518	0.1931 %	35 M $
First Trust Advisors LP 0.1860 %	1,229,570	0.1860 %	34 M $
U.S. Trust Company of Delaware 0.1677 %	1,109,117	0.1677 %	30 M $

Name	Equities	%	Valuation
GENMAB A/S 2.85%	1,881,559	2.85%	527,754,194 $

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B
INSMED INCORPORATED	+83.45%	9.17B

Bio Therapeutic Drugs